Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 2 of 3: Mean cell count and mean normalized growth rate inhibition values across all replicates. - Dataset (ID:20257)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Omipalisib | 0.01 | uM | 1 | 156.25 | 31.46 | 32.33 | 70.42 | 0.4664 | 0.0281 |
| MCF7 | Methotrexate | 0.0033113 | uM | 1 | 156.25 | 31.46 | 52.67 | 70.42 | 0.7685 | 0.6091 |
| MCF7 | Palbociclib | 0.01 | uM | 1 | 156.25 | 31.46 | 63.00 | 70.42 | 0.9117 | 0.8741 |
| MCF7 | Methotrexate | 0.0016596 | uM | 1 | 156.25 | 31.46 | 108.67 | 70.42 | 1.5518 | 1.9348 |
| MCF7 | Taxol | 1 | uM | 1 | 156.25 | 31.46 | 35.00 | 70.42 | 0.5012 | 0.0982 |
| MCF7 | Omipalisib | 0.31623 | uM | 1 | 156.25 | 31.46 | 31.00 | 70.42 | 0.4374 | -0.0273 |
| MCF7 | Methotrexate | 0.031623 | uM | 1 | 156.25 | 31.46 | 79.67 | 70.42 | 1.1536 | 1.3057 |
| MCF7 | Methotrexate | 0.31623 | uM | 1 | 156.25 | 31.46 | 98.00 | 70.42 | 1.4574 | 1.8884 |
| MCF7 | Methotrexate | 1 | uM | 1 | 156.25 | 31.46 | 53.67 | 70.42 | 0.7554 | 0.5407 |
| MCF7 | Taxol | 0.00016596 | uM | 1 | 156.25 | 31.46 | 70.33 | 70.42 | 1.0260 | 1.0866 |
| MCF7 | Taxol | 0.00033113 | uM | 1 | 156.25 | 31.46 | 64.33 | 70.42 | 0.8919 | 0.7560 |
| SK-BR-3 | Etoposide | 19.9526 | uM | 4 | 156.25 | 63.10 | 39.00 | 73.58 | 0.5278 | -0.8379 |
| SK-BR-3 | Nilotinib | 0.0033113 | uM | 4 | 156.25 | 63.10 | 70.67 | 73.58 | 0.9622 | 0.8203 |
| SK-BR-3 | Etoposide | 3.1623 | uM | 4 | 156.25 | 63.10 | 70.00 | 73.58 | 0.9414 | 1.1203 |
| SK-BR-3 | Etoposide | 10 | uM | 4 | 156.25 | 63.10 | 55.00 | 73.58 | 0.7462 | -0.4156 |
| SK-BR-3 | Nilotinib | 0.01 | uM | 4 | 156.25 | 63.10 | 83.00 | 73.58 | 1.1203 | 2.0389 |
| SK-BR-3 | Etoposide | 0.1 | uM | 4 | 156.25 | 63.10 | 62.67 | 73.58 | 0.8648 | 3.0356 |
| SK-BR-3 | Etoposide | 0.031623 | uM | 4 | 156.25 | 63.10 | 78.67 | 73.58 | 1.0645 | 1.6947 |
| SK-BR-3 | Etoposide | 0.31623 | uM | 4 | 156.25 | 63.10 | 72.00 | 73.58 | 0.9726 | 1.2279 |
| SK-BR-3 | Etoposide | 0.0033113 | uM | 4 | 156.25 | 63.10 | 107.33 | 73.58 | 1.4429 | 8.6318 |
| SK-BR-3 | Etoposide | 0.01 | uM | 4 | 156.25 | 63.10 | 71.33 | 73.58 | 0.9617 | 1.0565 |
| SK-BR-3 | Etoposide | 1 | uM | 4 | 156.25 | 63.10 | 52.33 | 73.58 | 0.7136 | -0.5718 |
| SK-BR-3 | Nilotinib | 0.031623 | uM | 4 | 156.25 | 63.10 | 82.33 | 73.58 | 1.1284 | 13.7620 |
| SK-BR-3 | Nilotinib | 0.31623 | uM | 4 | 156.25 | 63.10 | 68.00 | 73.58 | 0.9128 | 1.4711 |
| SK-BR-3 | Nilotinib | 0.1 | uM | 4 | 156.25 | 63.10 | 78.00 | 73.58 | 1.0560 | 2.1455 |